# MTAPESTRY 103 (NCT06360354)

> A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06360354
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
- Interventions: Anvumetostat; Gemcitabine; Nab-paclitaxel; Modified FOLFIRINOX; RMC-6236
- Enrollment: 120
- Primary outcome: Number of Participants Experiencing Dose Limiting Toxicities (DLT)
- Primary outcome: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)
- Primary outcome: Number of Participants Experiencing Serious Adverse Events (SAE)

## Indexed commentary on MTAPESTRY 103 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=mtapestry-103-nct06360354